$ACRX to 7$
In December AcelRx published clinical data in „The Journal of Universal Surgery“ titled „A Medication Use Evaluation of Sufentanil Sublingual Tablet 30 mcg for the Perioperative Management of Surgical Pain“.
What is DSUVIA? According to AcelRx DSUVIA is a recently approved drug „indicated for use in adults in certified medically supervised healthcare settings for the management of acute pain severe enough to require an opiod analgesic.“
The US army recently awarded AcelRX with a ~3.6M contract in order to purchase for the drug DSUVIA to support a study made by the US army as well as purchases for the stocking of their medical equipment for troop deployment and additional purchases by other branches of the military following the recent approval of DSUVIA.
AcelRx estimates that DSUVIA has the potential to reach over 11B in annual revenues. To put that into perspective - in 2019 they posted revenues of only 2.29M.
Technical Analysis is currently at a crucial point as price will soon break the symetric triangle in either direction - it will most likely be a movement in the upper direction as the Fibo Levels of the recent upwards trend as well as the $2.00 level act as strong support in combination with the good fundamental data.
Most institutional investors also seem to hold a bullish bias according to the data my broker provides.
What is DSUVIA? According to AcelRx DSUVIA is a recently approved drug „indicated for use in adults in certified medically supervised healthcare settings for the management of acute pain severe enough to require an opiod analgesic.“
The US army recently awarded AcelRX with a ~3.6M contract in order to purchase for the drug DSUVIA to support a study made by the US army as well as purchases for the stocking of their medical equipment for troop deployment and additional purchases by other branches of the military following the recent approval of DSUVIA.
AcelRx estimates that DSUVIA has the potential to reach over 11B in annual revenues. To put that into perspective - in 2019 they posted revenues of only 2.29M.
Technical Analysis is currently at a crucial point as price will soon break the symetric triangle in either direction - it will most likely be a movement in the upper direction as the Fibo Levels of the recent upwards trend as well as the $2.00 level act as strong support in combination with the good fundamental data.
Most institutional investors also seem to hold a bullish bias according to the data my broker provides.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.